arrow
M

Marij J.P. Welters

leiden university medical center
H指数:51
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells

T细胞免疫监测:定量和表征人抗原特异性T细胞的传统方法与新方法的比较分析

2026-10-060
PRE
The local cellular response to Human Papillomavirus focuses on basal layer restoration as visualized in situ by specific cellular neighborhoods near infected cells

局部细胞对Human Papillomavirus的应答集中在基底层的恢复,如通过感染细胞附近的特定细胞区域在原位可视化所见。

2025-12-080
OAAI
Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy

接受初始化放疗的宫颈癌女性患者骨髓脂肪分数和免疫细胞计数的变化

2025-08-090
OAAI
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study

Emmers, M.; Welters, M.J.P.; Dietz, M.V.; Santegoets, S.J.; Boekesteijn, S.; Stolk, A.; Loof, N.M.; Dumoulin, D.W.; Geel, A.L.; Steinbusch, L.C.; et al. TEIPP-vaccination在耐药性非小细胞肺癌中的研究:一项首次人体I/II期剂量递增研究。Nat. Commun. 2025, 16, 4958. [Google Scholar] [CrossRef]

2025-05-280
OAAI
APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma—a multicenter, single-arm, phase II, clinical proof-of-concept study

APOLLO:原发性外阴鳞状细胞癌的新辅助帕博利珠单抗治疗——一项多中心、单臂、II期概念验证临床研究

2025-04-170
OAAI
Inhibiting the NADase CD38 improves cytomegalovirus-specific CD8+Tcell + Tcell functionality and metabolism
2024-07-020
OAAI
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma
2024-06-300
OAAI
AUTOANTIBODY-POSITIVITY BEFORE TREATMENT IS ASSOCIATED WITH IMMUNE-RELATED ADVERSE EVENTS IN MELANOMA PATIENTSTREATED WITH ANTI-PD-1

治疗前的自身抗体阳性与接受抗PD-1治疗的黑色素瘤患者的免疫相关不良事件相关

2024-06-010
PRE
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment

肿瘤源性GDF-15阻断LFA-1依赖性T细胞募集并抑制对anti-PD-1治疗的反应

2023-07-2024
OAAI
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

与优化的Toll样受体2配体结合的HPV-16 E6合成肽的皮内疫苗接种在HPV-16阳性 (前) 恶性病变患者中显示出安全性和有效的T细胞免疫原性

2022-10-1916
OAAI